Table 2 Baseline demographic information and disease characteristics, inflammation status, therapy distribution according to mucosal healing status

Age, year, mean (SD)

47.02 (13.11)

49.50 (14.10)

0.40

Male, n (%)

37 (62.71)

18 (56.25)

0.547

Disease duration of UC, years (SD)

4.19 (4.97)

5.47 (8.08)

0.42

Newly diagnosed cases (%)

9 (15.25)

2 (6.25)

0.208

Hospital stay length, days (SD)

15.58 (11.58)

5.25 (3.88)

 < 0.001

Frequency of bowel movements, times/day (SD)

6.66 (3.86)

2.16 (1.68)

 < 0.001

Hematochezia, n (%)

55 (93.22)

12 (37.5)

 < 0.001

WBC count, *10^9/L, (SD)

8.01 (3.02)

6.05 (2.20)

 < 0.001

Hemoglobin, g/L, (SD)

109.14 (24.80)

135.16 (19.17)

 < 0.001

Hct, %, (SD)

33.98 (6.85)

40.97 (4.74)

 < 0.001

Platelet count, *10^9/L, (SD)

327.17 (110.98)

229.31 (63,07)

 < 0.001

C-reactive protein, mg/L, (SD)

45.04 (51.89)

3.08 (6.37)

 < 0.001

ESR, mm/h, (SD)

27.15 (21.44)

7.53 (5.83)

 < 0.001

D-dimer, µg/L, (SD)

1740.27 (3724.00)

798.20 (2019.04)

0.189

Fecal Calprotectin (μg/g)

N = 36

N = 15

323.88 (285.57)

195.55 (315.50)

0.162

Albumin, g/L, (SD)

34.95 (5.65)

42.25 (5.10)

 < 0.001

Current therapy by 5-ASA (%)

49 (83.05)

28 (87.5)

0.797

Current corticosteroids drugs (%)

8 (13.56)

3 (9.38)

0.804

Current anti-TNF treatment (%)

1 (1.69)

0 (0)

1.000